Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum via the PEX13 Gene

Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum (PBD-ZSS) consist of three related diseases Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), and Infantile Refsum disease (IRD) that share overlapping phenotypes with severity ranging from ZS to IRD. The overall incidence of PBD-ZSS is estimated to be from 1:500,000 to 1:50,000 (Steinberg et al. 2012). Common clinical features to all three include neurodevelopmental delay, glaucoma, retinal dystrophy, impaired hearing, renal cysts, and hepatic dysfunction (Wanders and Waterham 2005). Zellweger syndrome (ZS) is the most severe with neonatal onset, and characterized by typical craniofacial dysmorphism and profound hypotonia, severe seizures, and inability to feed. Infants with ZS usually do not make any developmental progress and rarely survive the first year of life. Compared to ZS, patients with NALD have less severe hypotonia and seizures during infancy and may reach school age. IRD is the least severe form. Patients with IRD show variable developmental delay and often present predominantly with vision problems, sensorineural hearing loss, and liver dysfunction. Most affected patients can reach childhood and, in rare cases, survive into adulthood. It has been suggested that a peroxisome biogenesis disorder should be considered in any individuals manifesting both vision and hearing problems. Biochemical findings of a PBD-ZSS patient include elevated plasma VLCFAs (C24:0 and C26:0), phytanic acid, and pipecolate and deficient plasmalogen synthesis in erythrocytes or cultured fibroblasts. A disparity of biochemical results obtained from different specimens (plasma, cultured cells or tissues) has been reported in milder patients due to peroxisomal mosaicism. Treatments of PBD-ZSS focus on symptomatic therapy (Steinberg et al. 2012; Steinberg et al. 2006).

PBD-ZSS are all autosomal recessively inherited and caused by pathogenic variants in one of PEX genes required for normal peroxisome assembly and/or peroxisomal protein import. The clinical severity is generally correlated with the impact of a given mutation on peroxisome formation and function (Ebberink et al. 2011). At least 13 PEX genes have been reported to be involved with PBD-ZSS (Smith and Aitchison 2013).

PEX13 encodes one of the peroxisomal membrane proteins and plays a role in importing peroxisomal matrix proteins. Currently, about ten PEX13 pathogenic variants were reported in less than 2% of studied patients, including missense, nonsense, splicing site mutations, small deletions, and a gross deletion (Steinberg et al. 2004; Waterham and Ebberink 2012; Al-Dirbashi et al. 2009).

In a cohort of 1077 patients with PBD-ZSS, 18 patients (1.7%) were identified with causative PEX13 mutations (Waterham and Ebberink 2012).

Clinical sensitivity for del/dup testing is expected to be low. A single gross deletion affecting the whole PEX13 gene has been reported in a patient with classical Zellweger syndrome (Al-Dirbashi et al. 2009).

This test is performed using Next-Gen sequencing with additional Sanger sequencing as necessary.

This test provides full coverage of all coding exons of the PEX13 gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing.